Clinical Trial Detail

NCT ID NCT01913639
Title FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib

Age Groups: adult

No variant requirements are available.